Refractory Large B-cell Lymphoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Refractory Large B-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 2

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma
Massachusetts General Hospital30 enrolled2 locationsNCT06811272
Recruiting
Phase 1Phase 2

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.112 enrolled15 locationsNCT05800977
Recruiting
Phase 2

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 2

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Relapsed/Refractory Large B-Cell Lymphoma
Peter MacCallum Cancer Centre, Australia40 enrolled6 locationsNCT06414148
Recruiting
Phase 2

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China89 enrolled1 locationNCT06489808
Recruiting
Phase 1Phase 2

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+3 more
Curocell Inc.91 enrolled1 locationNCT04836507